de.advfn.com/...s=ilns&p=0&t=1&dm=1&vol=1&
Anzeige
Meldung des Tages: Die USA schlagen Alarm: Dieses kritische Metall könnte der nächste Rohstoff-Superzyklus werden
ILNS mit riesigen news
WerbungPassende Knock-Outs auf Boeing Company
| Strategie | Hebel | |||
| Steigender Boeing Company-Kurs | 5,02 | 10,26 | 16,52 | |
| Fallender Boeing Company-Kurs | 6,04 | 10,34 | 18,96 | |
Den Basisprospekt sowie die Endgültigen Bedingungen finden Sie jeweils hier: DE000NB4PMV2
, DE000NB4YNT6
, DE000NB42GU3
, DE000NB3A5H6
, DE000NG8P9U8
, DE000NG8QK13
. Bitte informieren Sie sich vor Erwerb ausführlich über Funktionsweise und Risiken der Produkte. Bitte beachten Sie auch die weiteren Hinweise zu dieser Werbung.
Beiträge:
28
Zugriffe: 2.370 / Heute: 3
Zugriffe: 2.370 / Heute: 3
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi IBEX 35 Doble Apalancado Diario (2x) UCITS ETF Acc
Perf. 12M: +128,17%
Amundi MSCI Greece UCITS ETF Dist
Perf. 12M: +59,79%
Amundi IBEX 35 UCITS ETF Acc
Perf. 12M: +56,36%
Amundi IBEX 35 UCITS ETF Dist
Perf. 12M: +55,74%
Intellect Neurosciences, Inc. Obtains New Patent for Alzheimer's Vaccine From the United States Patent and Trademark Office ("US
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that it has received a new patent from the United States Patent and Trademark Office ("USPTO") in relation to the Company's RECALL-VAXTM technology platform. Patents for RECALL-VAXTM have been issued in Europe, Australia, New Zealand and South Africa, and corresponding patent applications are pending in Canada, China, Japan and Israel. RECALL-VAXTM is a method to immunize people to produce highly specific natural antibodies against the beta amyloid ("Aβ") protein before it causes irreversible damage by accumulating in the brains of Alzheimer's patients. The vaccine has the potential to delay onset or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor. The approach can be applied to additional therapeutic targets associated with Alzheimer's and other neurodegenerative conditions. Professor Benjamin Chain, Department of Immunology, UCL School of Life and Medical Sciences, London, UK, is the inventor of RECALL-VAXTM. Professor Chain, brother of Dr. Daniel Chain, Intellect's Chairman and Chief Executive Officer, is a member of the Company's scientific advisory board.
Dr. Daniel Chain commented: "This new patent from the USPTO is yet another important milestone for the Company and is indicative of the type of ground breaking research we do that is aimed at discovering and developing drugs that can fundamentally transform the way Alzheimer's disease is treated and ultimately prevent the onset of the disease. Intellect has two immunotherapy approaches: The more advanced of the two is the ANTISENILIN® platform, which uses recombinant monoclonal antibodies as highly specific drugs to prevent the accumulation of soluble Aβ in the brains of Alzheimer's patients. The ANTISENILIN® technology underlies products under development by major pharmaceutical companies, such as Ponezumab in Phase 2 and Bapineuzumab in Phase 3 clinical trials, respectively. RECALL-VAXTM pinpoints the same unique molecular signatures at the ends of Aβ to reproduce the same type of specificity that can be obtained using ANTISENILIN® monoclonal antibodies. However, instead of administering antibodies to patients, RECALL-VAXTM involves injecting a small piece of Aβ coupled to an innocuous bacterial protein with the goal of allowing the patient's immune system to generate antibodies that uniquely bind Aβ. A vaccine of this nature, which is analogous to a flu shot, could be viewed as the ultimate quest in Alzheimer's research. We look forward to developing drug candidates based on RECALL-VAXTM technology with the aim of ultimately testing the vaccine in human clinical trials."
About Alzheimer's Disease
Alzheimer's disease, the most common form of dementia, is characterized by progressive loss of memory and cognition, ultimately leading to complete debilitation and death. A hallmark feature of Alzheimer's pathology is the presence of insoluble protein deposits, known as amyloid beta, on the surface of nerve cells, which results from the accumulation of soluble neurotoxic amyloid beta in the brain. The effects of the disease are devastating to patients as well as their caregivers, with significant associated health care costs. It is estimated that there are more than five million Americans and about 30 million people worldwide suffering from Alzheimer's disease, with the number expected to increase dramatically as the global population ages. Currently-marketed drugs transiently affect some symptoms of the disease, but there are no drugs on the market today that slow or arrest the progression of the disease. In the United States, Medicare spending on Alzheimer's disease is estimated to total $160 billion this year.
About Intellect Neurosciences, Inc.
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that it has received a new patent from the United States Patent and Trademark Office ("USPTO") in relation to the Company's RECALL-VAXTM technology platform. Patents for RECALL-VAXTM have been issued in Europe, Australia, New Zealand and South Africa, and corresponding patent applications are pending in Canada, China, Japan and Israel. RECALL-VAXTM is a method to immunize people to produce highly specific natural antibodies against the beta amyloid ("Aβ") protein before it causes irreversible damage by accumulating in the brains of Alzheimer's patients. The vaccine has the potential to delay onset or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor. The approach can be applied to additional therapeutic targets associated with Alzheimer's and other neurodegenerative conditions. Professor Benjamin Chain, Department of Immunology, UCL School of Life and Medical Sciences, London, UK, is the inventor of RECALL-VAXTM. Professor Chain, brother of Dr. Daniel Chain, Intellect's Chairman and Chief Executive Officer, is a member of the Company's scientific advisory board.
Dr. Daniel Chain commented: "This new patent from the USPTO is yet another important milestone for the Company and is indicative of the type of ground breaking research we do that is aimed at discovering and developing drugs that can fundamentally transform the way Alzheimer's disease is treated and ultimately prevent the onset of the disease. Intellect has two immunotherapy approaches: The more advanced of the two is the ANTISENILIN® platform, which uses recombinant monoclonal antibodies as highly specific drugs to prevent the accumulation of soluble Aβ in the brains of Alzheimer's patients. The ANTISENILIN® technology underlies products under development by major pharmaceutical companies, such as Ponezumab in Phase 2 and Bapineuzumab in Phase 3 clinical trials, respectively. RECALL-VAXTM pinpoints the same unique molecular signatures at the ends of Aβ to reproduce the same type of specificity that can be obtained using ANTISENILIN® monoclonal antibodies. However, instead of administering antibodies to patients, RECALL-VAXTM involves injecting a small piece of Aβ coupled to an innocuous bacterial protein with the goal of allowing the patient's immune system to generate antibodies that uniquely bind Aβ. A vaccine of this nature, which is analogous to a flu shot, could be viewed as the ultimate quest in Alzheimer's research. We look forward to developing drug candidates based on RECALL-VAXTM technology with the aim of ultimately testing the vaccine in human clinical trials."
About Alzheimer's Disease
Alzheimer's disease, the most common form of dementia, is characterized by progressive loss of memory and cognition, ultimately leading to complete debilitation and death. A hallmark feature of Alzheimer's pathology is the presence of insoluble protein deposits, known as amyloid beta, on the surface of nerve cells, which results from the accumulation of soluble neurotoxic amyloid beta in the brain. The effects of the disease are devastating to patients as well as their caregivers, with significant associated health care costs. It is estimated that there are more than five million Americans and about 30 million people worldwide suffering from Alzheimer's disease, with the number expected to increase dramatically as the global population ages. Currently-marketed drugs transiently affect some symptoms of the disease, but there are no drugs on the market today that slow or arrest the progression of the disease. In the United States, Medicare spending on Alzheimer's disease is estimated to total $160 billion this year.
About Intellect Neurosciences, Inc.
warum muss man einen neuen thread eröffnen!
hmm
lg
hmm
lg
wie im lotto alles ist möglich!
kaufe aktien die keiner mehr haben will
und am ende wird alles gut!
kaufe aktien die keiner mehr haben will
und am ende wird alles gut!
wo wir heute hin fliegen :-)
das war ganz dünn. wird heute am start sofort die 004 knacken
ein schöner gapper
200k auf der 0,0027$ , scheint ein leichter wiederstand zu sein
Es gibt keine neuen Beiträge.
|
WerbungPassende Knock-Outs auf Boeing Company
| Strategie | Hebel | |||
| Steigender Boeing Company-Kurs | 5,02 | 10,26 | 16,52 | |
| Fallender Boeing Company-Kurs | 6,04 | 10,34 | 18,96 | |
Den Basisprospekt sowie die Endgültigen Bedingungen finden Sie jeweils hier: DE000NB4PMV2
, DE000NB4YNT6
, DE000NB42GU3
, DE000NB3A5H6
, DE000NG8P9U8
, DE000NG8QK13
. Bitte informieren Sie sich vor Erwerb ausführlich über Funktionsweise und Risiken der Produkte. Bitte beachten Sie auch die weiteren Hinweise zu dieser Werbung.
Neueste Beiträge aus dem Intellect Neurosciences Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 1 | US Bio Rakete ! | Theologe | Theologe | 26.10.11 17:54 | ||
2 | 27 | ILNS mit riesigen news | green2011 | Theologe | 26.10.11 16:01 | |
| 14 | habe mir heute welche gegönnt! | ARTNER514 | KungFuMaus | 31.03.11 18:59 |